Dr. Fetzer joined from SGI from Cerulean Pharma Inc., a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics, where he was President and CEO for five years. Under Dr. Fetzer’s leadership, Cerulean advanced from a pre-clinical platform company to become a publicly traded clinical development stage company with a pipeline of product candidates. Prior to Cerulean Pharma, Dr. Fetzer served in a variety of positions at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Research & Development, Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Business Development. Dr. Fetzer began his career in 1993 in various positions of increasing responsibility at the Boston Consulting Group (BCG), a global leading management consulting firm, including Consultant, Project Leader, Principal, Partner and Managing Director.

Dr. Fetzer served on the boards of Auxilium Pharmaceuticals, Inc. from 2005 to 2015 and Cerulean Pharma, Inc. from 2009 to 2014, and has served on the board of Tecan Group AG since 2011. Dr. Fetzer received a B.S. in Biochemistry from the College of Charleston, his Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an MBA from Carnegie Mellon University.

Dr. J. Craig Venter is regarded as one of the leading scientists of the 21st century for his invaluable contributions in genomic research, most notably for the first sequencing and analysis of the human genome published in 2001 and the most recent and most complete sequencing of his diploid human genome in 2007. Dr. Venter provides visionary guidance and strategic scientific direction for the company. Craig is also Co-founder, CEO and Executive Chairman of Human Longevity Inc. (HLI) and CEO and Chairman of the not-for-profit J. Craig Venter Institute. He and his teams have sequenced more than 300 organisms including human, fruit fly, mouse, rat, and dog as well as numerous microorganisms and plants. Craig is also the key leader in the field of synthetic genomics. He and his team at JCVI constructed the first synthetic bacterial cell, work that is leading to extraordinary advances in engineering microorganisms for many vital applications used at SGI.

Craig is the author of more than 200 research articles and is among the most cited scientists in the world. He is the recipient of numerous honorary degrees and scientific awards including the 2008 National Medal of Science. Craig is also a member of many prestigious scientific organizations including the National Academy of Sciences.

Dr. Hamilton Smith is Co-Chief Scientific Officer at SGI and Scientific Director of the Synthetic Biology team at the J. Craig Venter Institute. Hamilton received the 1978 Nobel Prize for his work on the discovery of restriction enzymes, which are essential tools used in the field of recombinant DNA technology. He is widely considered one of the experts in DNA library construction and DNA manipulation techniques. Hamilton was formerly the senior director of DNA Resources at Celera Genomics. Prior to joining Celera, he joined the scientific team at The Institute for Genomic Research, a position he held after leaving the Johns Hopkins University where he was professor of molecular biology and genetics. He is a member of the National Academy of Sciences.

Mr. Artuso is an accomplished executive and entrepreneur with broad domestic and international experience in biotech, clean energy, finance, public policy, and sustainable development. Before joining SGI, Anthony spent six years with Merck KGaA where he managed strategic planning and business development and also served as general manager for the company’s protein and cellular analysis business. In previous business roles, Anthony managed strategic planning, new product development, technology licensing, and acquisitions for Bristol Myers-Squibb and Vertex Pharmaceuticals. Anthony has also served as a faculty member at the University of Charleston and Rutgers University. While in academia, he became recognized internationally for his work on the chemical and genetic value of biodiversity. His academic research and consulting activities included serving as advisor to the World Bank and various U.S. government and multi-national agencies. Anthony also assisted the United Nations Conference on Trade and Development in designing and launching the BioTrade Initiative, an international program to promote sustainable development of biological resources. During an earlier career in the public sector, Anthony constructed a blueprint for the deregulation of US electricity generation, directed a billion dollar capital improvement program for a major US city, designed and implemented regional water pollution control programs, and served as Chief Financial Officer of a public sector utility.

Anthony holds a Bachelor’s degree in Environmental Science from Columbia University, a Master’s Degree from the Kennedy School of Government at Harvard, and a Ph.D. in Natural Resource Policy and Management from Cornell.

Mr. Cutler joined Synthetic Genomics as General Counsel in 2016.  Prior to joining SGI, Rob was General Counsel and Corporate Secretary at LifeVantage Corporation from 2011-2015 where he was responsible for all legal, regulatory, and compliance activities, managed all securities filings, and led expansion into multiple foreign jurisdictions. Rob also served as Associate General Counsel and Senior Director, Business Development at Biogen Idec Inc. from 2001-2010 where he managed business development efforts for the oncology business unit and closed over $1.5 billion in transactions including acquisitions, multi-product collaborations, strategic alliances, product divestitures and research and academic collaborations. Prior to joining Biogen Idec, Rob spent several years in private law practice with two large full service law firms where he counseled both private and public companies in securities matters, general corporate transactions and mergers and acquisitions.

Rob received his Juris Doctor (JD) degree, graduating cum laude from the Brigham Young University J. Reuben Clark Law School.

Joseph Mahler joined SGI in 2011. Previously, Joe was CFO at FuelCell Energy Inc, a publicly-traded developer and manufacturer of ultra-clean stationary fuel cell power plants, where he had been employed since 1998. He played a leading role at the company as Senior Vice-President, CFO, Corporate Treasurer and Secretary. In these roles, he raised more than $700 million from public offerings. He was instrumental in helping shape the company’s business strategy as they grew from 120 employees to more than 400 and expanded operations to serve global markets in Europe and Asia. Prior to his employment with FuelCell Energy, Mahler was the VP and CFO for Earthgro Inc. where he worked closely with the CEO and management to significantly increase sales and profitability. Earlier in his career, he was a partner with the accounting firm Ernst & Young and was employed from 1974 to 1992.

Mahler received a Bachelor of Science degree in accounting from Boston College in 1974, and his certification as a public accountant in 1978.

Dr. Peterson has over 25 years experience in industrial research and development in the areas of molecular biology, nucleic acids and genomics product and technology development. His experience encompasses clinical diagnostics, life science research tools and pharmaceutical discovery technologies and market segments. Prior to joining SGI, Dr. Peterson led Genomics and Synthetic Biology R&D at Life Technologies, a global leader in life science research tools. Prior to Life Technologies, Dr. Peterson held research and development positions with increasing responsibilities at Genicon Sciences, Trega Biosciences, Hybritech and Gen-Probe where he focused on product and technology research, development and commercialization.

Dr. Peterson was a postdoctoral fellow at the Max Planck Institute in Cologne Germany and received his Ph.D. in Microbiology at the University of Southern California School of Medicine.

Mr. Wood is President of SGI-DNA, Instruments, and Reagents. Prior to joining Synthetic Genomics he was General Manager at Thermo Fisher Scientific’s (formerly Life Technologies) Synthetic Biology business unit. He had worked at Life Technologies since 2004 in roles of increasing responsibility including acquiring and integrating two businesses. Mr. Wood has 24 years of leadership experience in product development, marketing and sales from his work at QIAGEN and Life Technologies. Prior to joining Life Technologies, he was Director of Sales for QIAGEN, where he led commercial operation in North America for the life science research and molecular diagnostics businesses.

Mr. Wood holds a Bachelor of Science degree from Oregon State University and has a number of scientific publications in the scientific area of molecular biology.

Ms. Bowman joined Synthetic Genomics as Senior Director, Human Resources in 2012 and was appointed to Vice President, Human Resources in January 2014. Ms. Bowman has more than 15 years of experience in the field of Human Resources. She held positions in start-up and Fortune 500 companies including ACADIA Pharmaceuticals, Pfizer Inc. and Agouron Pharmaceuticals. In addition to experience in the life sciences, she has also led human resources in a variety of diverse industries.

Ms. Bowman received a B.S in Business Management from San Diego State University.

Mr. Chiarelli joined SGI in December of 2015 as the Vice President of Corporate Development and Strategy. He is responsible for, in partnership with the executive team, defining, evolving and implementing SGI’s strategy across all of its franchises with a focus on value creation. In that context, Ben facilitates and manages the portfolio of internal initiatives, strategic partnerships and transactions from inception to closing including sourcing, funding, negotiation and post-deal integration, execution, and monitoring. Mr. Chiarelli is also responsible for managing investor and media relations in partnership with the CFO. Ben joined SGI from Millennium Health, a leading medication solutions company, where he led the strategy and corporate development efforts. Prior to joining industry, Mr. Chiarelli had a nine year tenure on Wall Street, most recently with J.P. Morgan’s healthcare investment banking group where he advised clients on mergers and acquisitions as well as debt and equity capital markets financings. In his career on Wall Street, he executed over $20 billion in transactions.

Mr. Chiarelli earned his MBA from Carnegie Mellon University’s Tepper School of Business and his B.S. in Mechanical Engineering from Case Western Reserve University. Ben serves on the board of American Made Liner Systems and is a Founder/Director of the 32/21 foundation, a college scholarship charity founded in his brother’s honor.

Dr. Gibson, inventor of Gibson Assembly^®, joined SGI in February of 2011 after spending more than six years at the J. Craig Venter Institute (JCVI) where he co-led the team that constructed the first synthetic bacterial genome in 2008 and the first synthetic cell in 2010. He had an immediate impact on SGI by bringing the synthetic genomics tools he developed at JCVI to SGI. Dr. Gibson led the DNA technologies team that developed a rapid approach for producing accurate influenza genes used in synthetic flu vaccine production in 2013 and synthesized the first minimal cell in 2016 together with JCVI scientists. Dr. Gibson co-founded SGI-DNA in 2013 and, with his team of scientists, formed the foundational technology that drives the BioXp and the Digital to Biological Converter (DBC) and continue to develop new, cutting edge tools for whole genome design, synthesis and assembly, and activation.

Dr. Gibson earned his Ph.D. in Molecular Biology from the University of Southern California. Before earning his Ph.D., he earned his Bachelor’s degree in Biological Sciences from the State University of New York at Buffalo.

Dr. Hubby has spent more than thirteen years in the biotechnology industry leading product development efforts from early concept stages into clinical evaluation. Prior to joining, Dr. Hubby was at Liquidia Technologies, a nanotechnology company, where she helped build and lead the company’s life science business and vaccine focus. As Executive Director of Vaccines, she helped advance Liquidia’s platform technology into the clinic and built a portfolio of programs that attracted a major licensing deal with a leading pharmaceutical partner. Prior to Liquidia, Dr. Hubby was the Head of Discovery Immunology at AlphaVax, Inc., where she designed and developed RNA replicon vaccine candidates for infectious disease and cancer immunotherapy targets and many of these were advanced into clinical evaluation.

Dr. Hubby received her Ph.D degree from the University of Georgia, Department of Cellular Biology and Center for Tropical and Emerging Diseases.

Dr. Toby Richardson has more than 20 years of experience in the fields of bioinformatics, enzymology, and molecular biology. Prior to joining SGI Toby spent ten years at Diversa Corporation, where he established and managed the company’s informatics department. During this time his team developed some of the first tools to annotate, store and mine metagenomic information from environmental samples.

As a Post Doctoral Researcher at the Scripps Research Institute, he worked on isolation, cloning and structural characterization of human cytochrome P450s. Toby earned a B.Sc. Hons in Biochemistry and a Ph.D. in Molecular Toxicology, both from the University of Surrey, UK.

Dr. Teresa Spehar joined Synthetic Genomics in November, 2008 and manages all aspects of SGI’s intellectual property. In addition to overseeing SGI’s patent portfolio and counseling management regarding IP issues, she acts as liaison to the J. Craig Venter Institute to protect synthetic biology advances in collaborations between the organizations. Dr. Spehar has spent the last 15 years working as a patent attorney in both biotechnology companies and a national law firm in San Diego, CA. Prior to entering law school to focus on intellectual property, Dr. Spehar worked as a guest researcher at the Centers for Disease Control in Atlanta, GA.

She is a graduate of the Johns Hopkins University School of Medicine (Ph.D., Pharmacology and Molecular Sciences) and of California Western School of Law. She is admitted to practice in California and before the U.S. Patent and Trademark Office.

Mr. Warden joined Synthetic Genomics in June of 2013. Prior to joining SGI, he was Vice President of Engineering for IOS Technologies, where he completed a 3D Dental Impression and Restoration Manufacturing System for in-office use. Mr. Warden brings over 25 years of product development experience in the Medical Device and Laboratory Equipment industry, including 20 years of personnel and project management experience in an FDA/GMP environment. During his career, Mr. Warden has developed Class 1 thru 3 Medical Devices, including intravenous infusion pumps for IMED Corporation, non-invasive superconducting neural diagnostic systems for Biomagnetic Technologies, Inc., and a wavefront-based ophthalmic diagnostic device for Ophthonix , Inc. In the laboratory system field, Mr. Warden led mechanical development of Accumetric’s point-of-care whole blood assay system, as well as the instrument portion of Genicon Sciences’s system for ultra-low level detection of DNA, RNA, and proteins.

Mr. Warden holds more than 25 US patents and has received numerous awards for both the technical and design aspects of his developed products. Laurence graduated with a Bachelor of Arts in Industrial Engineering from San Diego State University.